Antisense Bcl-2 sensitizes prostate cancer cells to radiation

Zhaomei Mu, Paul Hachem, Alan Pollack

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

BACKGROUND. Bcl-2 is anti-apoptotic and overexpression is associated with prostate tumor aggressiveness. We hypothesized that Bcl-2 has a role in prostate cancer radiation (RT) response. The relationship of Bcl-2 expression in four prostate cancer cell lines, and the effect of modulating expression with a Bcl-2 antisense oligonucleotide (G3139, Genasense®, oblimersen sodium, Genta Incorporated), to RT was examined. METHODS. The four cell lines studied were LNCaP (wild type-p53), PCS (p53 null), Bcl-2 stably transfected LNCaP (LNCaP-BST), and Bcl-2 stably transfected PCS (PC3-BST) cells. Cells were treated with antisense (AS) Bcl-2 alone or with RT (2-6 Gy). Following RT, cells were processed at 3-6 hr for Western blots, 18 hr for Annexin V staining and flow cytometric analysis, 24 hr for caspases 3 + 7 quantification by fluorometric assay, and immediately for clonogenic survival. RESULTS. AS caused a significant reduction in Bcl-2 expression in all cell lines. P53 expression was elevated following RT treatment in LNCaP and LNCaP-BST cells. P21 was increased by RT treatment in all cell lines. AS caused a significant increase in caspase 3 + 7 activity over the mismatch (MM) controls in all cell lines. When AS was combined with RT, caspase 3 + 7 activity was further increased significantly over all other groups in all cell lines. Moreover, AS + RT resulted in significantly reduced clonogenic survival over MM + RT, which was dampened in the Bcl-2 overexpressing lines. CONCLUSIONS. To our knowledge, these data demonstrate for the first time that a Bcl-2 specific AS oligonucleotide sensitizes prostate cancer cells to RT. p53 is not required for this effect.

Original languageEnglish
Pages (from-to)331-340
Number of pages10
JournalProstate
Volume65
Issue number4
DOIs
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Radiation
Caspase 7
Cell Line
Caspase 3
Antisense Oligonucleotides
Annexin A5
Prostate
Western Blotting
Staining and Labeling
oblimersen
Neoplasms

Keywords

  • Antisense Bcl-2
  • Apoptosis
  • Prostate cancer
  • Radiation

ASJC Scopus subject areas

  • Urology

Cite this

Antisense Bcl-2 sensitizes prostate cancer cells to radiation. / Mu, Zhaomei; Hachem, Paul; Pollack, Alan.

In: Prostate, Vol. 65, No. 4, 01.12.2005, p. 331-340.

Research output: Contribution to journalArticle

Mu, Zhaomei ; Hachem, Paul ; Pollack, Alan. / Antisense Bcl-2 sensitizes prostate cancer cells to radiation. In: Prostate. 2005 ; Vol. 65, No. 4. pp. 331-340.
@article{879631c426fc4a20abe04240f181788b,
title = "Antisense Bcl-2 sensitizes prostate cancer cells to radiation",
abstract = "BACKGROUND. Bcl-2 is anti-apoptotic and overexpression is associated with prostate tumor aggressiveness. We hypothesized that Bcl-2 has a role in prostate cancer radiation (RT) response. The relationship of Bcl-2 expression in four prostate cancer cell lines, and the effect of modulating expression with a Bcl-2 antisense oligonucleotide (G3139, Genasense{\circledR}, oblimersen sodium, Genta Incorporated), to RT was examined. METHODS. The four cell lines studied were LNCaP (wild type-p53), PCS (p53 null), Bcl-2 stably transfected LNCaP (LNCaP-BST), and Bcl-2 stably transfected PCS (PC3-BST) cells. Cells were treated with antisense (AS) Bcl-2 alone or with RT (2-6 Gy). Following RT, cells were processed at 3-6 hr for Western blots, 18 hr for Annexin V staining and flow cytometric analysis, 24 hr for caspases 3 + 7 quantification by fluorometric assay, and immediately for clonogenic survival. RESULTS. AS caused a significant reduction in Bcl-2 expression in all cell lines. P53 expression was elevated following RT treatment in LNCaP and LNCaP-BST cells. P21 was increased by RT treatment in all cell lines. AS caused a significant increase in caspase 3 + 7 activity over the mismatch (MM) controls in all cell lines. When AS was combined with RT, caspase 3 + 7 activity was further increased significantly over all other groups in all cell lines. Moreover, AS + RT resulted in significantly reduced clonogenic survival over MM + RT, which was dampened in the Bcl-2 overexpressing lines. CONCLUSIONS. To our knowledge, these data demonstrate for the first time that a Bcl-2 specific AS oligonucleotide sensitizes prostate cancer cells to RT. p53 is not required for this effect.",
keywords = "Antisense Bcl-2, Apoptosis, Prostate cancer, Radiation",
author = "Zhaomei Mu and Paul Hachem and Alan Pollack",
year = "2005",
month = "12",
day = "1",
doi = "10.1002/pros.20303",
language = "English",
volume = "65",
pages = "331--340",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Antisense Bcl-2 sensitizes prostate cancer cells to radiation

AU - Mu, Zhaomei

AU - Hachem, Paul

AU - Pollack, Alan

PY - 2005/12/1

Y1 - 2005/12/1

N2 - BACKGROUND. Bcl-2 is anti-apoptotic and overexpression is associated with prostate tumor aggressiveness. We hypothesized that Bcl-2 has a role in prostate cancer radiation (RT) response. The relationship of Bcl-2 expression in four prostate cancer cell lines, and the effect of modulating expression with a Bcl-2 antisense oligonucleotide (G3139, Genasense®, oblimersen sodium, Genta Incorporated), to RT was examined. METHODS. The four cell lines studied were LNCaP (wild type-p53), PCS (p53 null), Bcl-2 stably transfected LNCaP (LNCaP-BST), and Bcl-2 stably transfected PCS (PC3-BST) cells. Cells were treated with antisense (AS) Bcl-2 alone or with RT (2-6 Gy). Following RT, cells were processed at 3-6 hr for Western blots, 18 hr for Annexin V staining and flow cytometric analysis, 24 hr for caspases 3 + 7 quantification by fluorometric assay, and immediately for clonogenic survival. RESULTS. AS caused a significant reduction in Bcl-2 expression in all cell lines. P53 expression was elevated following RT treatment in LNCaP and LNCaP-BST cells. P21 was increased by RT treatment in all cell lines. AS caused a significant increase in caspase 3 + 7 activity over the mismatch (MM) controls in all cell lines. When AS was combined with RT, caspase 3 + 7 activity was further increased significantly over all other groups in all cell lines. Moreover, AS + RT resulted in significantly reduced clonogenic survival over MM + RT, which was dampened in the Bcl-2 overexpressing lines. CONCLUSIONS. To our knowledge, these data demonstrate for the first time that a Bcl-2 specific AS oligonucleotide sensitizes prostate cancer cells to RT. p53 is not required for this effect.

AB - BACKGROUND. Bcl-2 is anti-apoptotic and overexpression is associated with prostate tumor aggressiveness. We hypothesized that Bcl-2 has a role in prostate cancer radiation (RT) response. The relationship of Bcl-2 expression in four prostate cancer cell lines, and the effect of modulating expression with a Bcl-2 antisense oligonucleotide (G3139, Genasense®, oblimersen sodium, Genta Incorporated), to RT was examined. METHODS. The four cell lines studied were LNCaP (wild type-p53), PCS (p53 null), Bcl-2 stably transfected LNCaP (LNCaP-BST), and Bcl-2 stably transfected PCS (PC3-BST) cells. Cells were treated with antisense (AS) Bcl-2 alone or with RT (2-6 Gy). Following RT, cells were processed at 3-6 hr for Western blots, 18 hr for Annexin V staining and flow cytometric analysis, 24 hr for caspases 3 + 7 quantification by fluorometric assay, and immediately for clonogenic survival. RESULTS. AS caused a significant reduction in Bcl-2 expression in all cell lines. P53 expression was elevated following RT treatment in LNCaP and LNCaP-BST cells. P21 was increased by RT treatment in all cell lines. AS caused a significant increase in caspase 3 + 7 activity over the mismatch (MM) controls in all cell lines. When AS was combined with RT, caspase 3 + 7 activity was further increased significantly over all other groups in all cell lines. Moreover, AS + RT resulted in significantly reduced clonogenic survival over MM + RT, which was dampened in the Bcl-2 overexpressing lines. CONCLUSIONS. To our knowledge, these data demonstrate for the first time that a Bcl-2 specific AS oligonucleotide sensitizes prostate cancer cells to RT. p53 is not required for this effect.

KW - Antisense Bcl-2

KW - Apoptosis

KW - Prostate cancer

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=28744451267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28744451267&partnerID=8YFLogxK

U2 - 10.1002/pros.20303

DO - 10.1002/pros.20303

M3 - Article

C2 - 16015611

AN - SCOPUS:28744451267

VL - 65

SP - 331

EP - 340

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -